Paramount Skydance has submitted remedies to the European Commission as it seeks approval for its $110bn acquisition of Warner Bros. Discovery, moving the transaction closer to a decision in Brussels. The Commission has extended its provisional deadline from July 7 to July 22 while it assesses the commitments, which have not been made public.
The submission changes the financial profile of the remaining approval process. Paramount agreed in February to acquire Warner Bros. Discovery for $31 a share in cash, valuing the business at $81bn on an equity basis and $110bn including debt. Warner Bros. Discovery shareholders are also due a $0.25-a-share ticking fee for each quarter, calculated daily, if the deal has not closed by September 30, 2026.
That mechanism turns regulatory delay into a direct transaction cost. The merger agreement also provides for a $7bn regulatory termination fee if the transaction fails because required approvals are not secured or a final antitrust or foreign-regulatory order prevents completion. The economics therefore depend not only on the purchase price and planned synergies, but on the scope, timing and implementation cost of any concessions accepted by the Commission.
The Commission has not disclosed what Paramount has offered. Press reports indicate that the package may involve ending a film-distribution joint venture with Universal Pictures, but that detail has not been confirmed by either the regulator or Paramount. Any structural remedy would need to be assessed against its effect on distribution revenue, contractual arrangements, working capital and the integration model prepared for the combined group.
The EU process follows a different course from the United States. The US Department of Justice closed its investigation on June 12 after an eight-month review, concluding that the transaction was unlikely to harm competition in streaming video, linear television or theatrical film production and distribution. The European Commission is also examining the transaction under the Foreign Subsidies Regulation, adding a separate review of the financial support behind the acquisition.
Funding is central to the deal’s execution. Paramount said the transaction is supported by $47bn of new equity backed by the Ellison Family and RedBird Capital Partners, alongside $54bn of debt commitments from Bank of America, Citi and Apollo. It expects more than $6bn of synergies and has projected net debt to EBITDA of 4.3 times at closing on a synergised basis, with investment-grade credit metrics targeted within three years.
The remedies review will determine whether those assumptions remain intact. A concession that changes distribution operations, asset ownership or market access could require revised synergy schedules, separation accounting and new financing sensitivities before completion. It may also affect the pace at which integration spending can begin and the point at which anticipated savings are recognised.
Paramount’s submission shows how regulatory commitments have become part of the capital plan in large cross-border acquisitions rather than a legal workstream running alongside it. Finance teams will need a clear bridge between the agreed remedy, the operating model and the debt-reduction timetable, with enough flexibility to absorb a later closing date or a more expensive package than originally modelled.
MORW FROM FINANCE MONTHLY - Bending Spoons Prices $29 IPO — Finance Monthly
